AACR 2022 | Treatments for HR+ postmenopausal breast cancer

Meenakshi Anurag, PhD, Baylor College of Medicine, Houston, TX, discusses a Phase III clinical trial (NCT00075764) that compared various therapies’ effectiveness on women with HR+ postmenopausal breast cancer. Patients were either treated with anastrozole (an aromatase inhibitor), fulvestrant (a selective oestrogen receptor degrader), or a combination of anastrozole and fulvestrant. It was found that a combination of anastrozole and fulvestrant was much more effective in treating the high-risk and pro-prognosis luminal B subtype compared to the luminal A subtype or nal luminal subtypes. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.